FCA
TGTX icon

Fortis Capital Advisors’s TG Therapeutics TGTX Stock Holding History

Fortis Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79M Buy
+50,719
New +$2.08M 0.31% 58
2023
Q2 		– Sell
-396
Closed -$5.96K – 568
2023
Q1 		$5.96K Hold
396
– – ﹤0.01% 490
2022
Q4 		$4.68K Buy
+396
New +$2.87K ﹤0.01% 520

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Fortis Capital Advisors's TGTX Position: Q2 2026 in Review

Fortis Capital Advisors opened a new position in TG Therapeutics (TGTX) in Q2 2026: 50,719 shares worth $2.79M. The stake represents 0.31% of the portfolio and ranks #58 among its holdings. This is a return to the name: Fortis Capital Advisors previously reported a position in TGTX as recently as Q1 2023.

Fortis Capital Advisors first reported a position in TGTX in Q4 2022 and has held it in 3 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Fortis Capital Advisors held 50,719 shares of TG Therapeutics worth $2.79M as of Q2 2026.
  • TG Therapeutics was a new Fortis Capital Advisors position in Q2 2026.
  • TG Therapeutics made up 0.31% of Fortis Capital Advisors's portfolio in Q2 2026, its #58 holding.
  • Fortis Capital Advisors first reported a position in TG Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Fortis Capital Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.